Abnova Taiwan Corp represents values such as innovation, collaboration, and integrity in its corporate philosophy. It focuses on developing and providing high-quality antibodies and other research tools to accelerate scientific discoveries. With a commitment to excellence and customer satisfaction, Abnova Taiwan Corp aims to support researchers worldwide in their pursuit of understanding human health and diseases. By continuously advancing scientific knowledge and delivering cutting-edge technologies, the company demonstrates its dedication to improving global healthcare and making a positive impact on society.

Abnova Taiwan Corp is primarily present in Taiwan.

Abnova Taiwan Corp has achieved significant milestones since its inception. The company has successfully developed over 20,000 high-quality antibodies and more than 3,000 recombinant proteins, establishing itself as a leader in the life sciences research industry. Abnova Taiwan Corp has also made considerable progress in the production of innovative diagnostic kits and pharmaceutical-related products. With its dedication to research and development, the company has gained recognition for its contributions to advancing biomedical research. Additionally, Abnova Taiwan Corp's collaborations with renowned academic institutions and pharmaceutical companies have further strengthened its position in the market.

Abnova Taiwan Corp is a renowned biotechnology company based in Taiwan. Established in 2002, it specializes in the development and commercialization of innovative tools and solutions for life science research. Abnova Taiwan Corp has a rich history of delivering high-quality products and services to researchers worldwide, empowering them to achieve breakthroughs in various fields including cancer research, drug discovery, and personalized medicine. With an extensive portfolio of antibodies, proteins, and assays, the company has gained recognition for its commitment to advancing scientific knowledge and improving human health. Abnova Taiwan Corp continues to be a leading player in the global biotechnology industry, dedicated to driving advancements and contributing to scientific discovery.

The main competitors of Abnova Taiwan Corp in the market include companies like Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, and Bio-Rad Laboratories.

Abnova Taiwan Corp is primarily active in the biotechnology industry.

The business model of Abnova Taiwan Corp is focused on bio-technology and life sciences. Abnova specializes in the production and distribution of high-quality antibodies and related reagents for academic and industrial researchers worldwide. By leveraging their extensive expertise in protein science and advanced technologies, Abnova aims to contribute to advancements in medical research and drug discovery. Abnova's products and services encompass a wide range of research areas including genomics, proteomics, cell biology, and diagnostics. Through their innovative solutions and commitment to quality, Abnova Taiwan Corp strives to support the scientific community in their pursuit of breakthrough discoveries and improved healthcare.

Pašreizējais KGV Abnova Taiwan nevar tikt aprēķināts.

KUV šobrīd Abnova Taiwan nevar aprēķināt.

AlleAktien kvalitātes vērtējums Abnova Taiwan ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu Abnova Taiwan.

Pašlaik peļņa Abnova Taiwan nevar tikt aprēķināta.

Abnova Taiwan Corp is an innovative company in the field of biotechnology, specializing in the development of products for medical research and diagnostics. The company is headquartered in Taiwan and operates worldwide. The business model of Abnova is based on three pillars: product development and distribution, diagnostics, and laboratory services. The company offers a wide range of products and services for medical research and diagnostics, working closely with customers and partners to meet their needs and requirements. Product development and distribution Abnova develops and produces antibodies, proteins, peptides, and other biological molecules for research and diagnostics in a variety of applications. The company works closely with its customers to meet specific needs and requirements in terms of quality, quantity, and functionality. Abnova also offers innovative products for personalized medicine, tailored to the individual needs of the patient. These products are based on the patient's genetic information, enabling precise diagnostics and treatment. Diagnostics Abnova offers numerous diagnostic products for medical research and diagnostics, including antibodies, proteins, peptides, kits, and assays. These products are used for biomarker identification, disease diagnosis and treatment, and personalized medicine. Laboratory services Abnova also offers extensive laboratory services for medical research and diagnostics, including protein production, peptide production, antibody production, assay development and validation, and diagnosis and treatment support. The company also has extensive experience in genetic analysis and offers corresponding services. Abnova always goes the extra mile to provide its customers with high-quality products and services. The company continuously invests in research and innovation to improve its products and processes and meet the challenges of medical research and diagnostics. In summary, Abnova Taiwan Corp is an innovative company in the field of biotechnology, offering a wide range of products and services for medical research and diagnostics to its customers. The business model of Abnova is based on the pillars of product development and distribution, diagnostics, and laboratory services, with the company continuously investing in research and innovation to provide its customers with high-quality products and services.

Abnova Taiwan izmaksā dividendes 0,46 TWD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Abnova Taiwan vai uzņēmums nedod dividendes.

Abnova Taiwan ISIN ir TW0004133004.

Abnova Taiwan simbols ir 4133.TW.

Pēdējo 12 mēnešu laikā Abnova Taiwan maksāja dividendes 0,80 TWD apmērā. Tas atbilst aptuveni 2,62 % dividendes ražībai. Nākamajos 12 mēnešos Abnova Taiwan plāno maksāt dividendes 0,80 TWD apmērā.

Abnova Taiwan pašreizējā dividendu rentabilitāte ir 2,62 %.

Abnova Taiwan maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos augusts, jūlijs, jūlijs, jūlijs.

Abnova Taiwan pēdējo 14 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,80 TWD. Tas atbilst dividendes ražībai 2,62 %.

Abnova Taiwan tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Abnova Taiwan apmērā 0,72 TWD, kas tika izmaksāta 27.06.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.06.2024..

Pēdējās dividendes izmaksa notika 27.06.2024..

Gadā 2023, Abnova Taiwan izmaksāja 0,46 TWD dividendes.

Abnova Taiwan dividendes tiek izmaksātas TWD.